Louis Garguilo
ARTICLES BY LOUIS
-
![SCHOTTimage]( "Your CDMO And Your Glass Vials: Best Practices For Development")
7/14/2020Today the mention of “vials” leads to questions of supplies for COVID-19 vaccines. But thoughts of vials normally pertain to your own drug develop program needs. For advice, I asked one of the biggest glass producers in the world.
-
![USA Puerto Rico Flag]( "But Where In The U.S.? Puerto Rico In The Reshoring Race")
7/9/2020We are refocused on drug development and manufacture in the U.S. But where in this big country makes the most dollars and sense for locating operations? One place drug manufacturing has traditionally flourished is Puerto Rico.
-
![Coronavirus in china.jpg]( "“We Forgot Our People”: The Time Outsourcing Might Have Stopped")
6/29/2020“But we forgot our people,” says an introspective biopharma executive, regarding pre-coronavirus risk assessments. Here's a look at what did and might have happened, and thoughts for the future of outsourcing.
-
![Glass Mirror Skyscraper.jpg]( "<em>Non-CDMOs</em> Serving Cell And Gene Therapy Developers")
6/22/2020There's a new cell-and-gene service organization out there: the non-CDMO. Here's who they are, an analysis of why they're different, and a look at how they can help you.
-
![NexusPlantRendering]( "Roadmap To U.S. Drug Manufacturing: Outsource And Build At Home")
6/17/2020Nexus Pharmaceuticals has laid out a roadmap - and is living proof - we can develop and manufacture even generics in the U.S. And that goes for both in-house and at CMOs.
-
![BioCentriqrendering]( "New Jersey Solutions For Cell And Gene Development and Manufacturing")
6/12/2020New Jersey’s first university-based, cell-and-gene-therapy development and manufacturing innovation center for-hire, was founded on solving three critical industry needs.
-
![US-ChinaDice]( "Drug Tariffing: How Trade Policy And Politics Manipulate Your Outsourcing")
6/8/2020Tariffs, historic trade policy, politics: Most likely not top-of-mind right now. Here’s why they should be, particularly for younger professionals at U.S. biotechs leveraging CDMOs.
-
![Pills Medication]( "The Oral Solid Dose Path To U.S. Partnerships")
5/28/2020OSD drugs are receiving the benefits of new technologies, formulation ideas, and other processing innovations. Can innovation pare COGs to open up more production in the U.S.? Here's our assessment.
-
![iStock-1131848229]( "Common Drugs Now Made In America!")
5/22/2020It begins in a typical flash hurled by our hyrdoxycloriquine President. A U.S. drug manufacturer gets up to $812 million in federal funding for advanced manufacturing of America's most essential medicines. More politics or real progress?
-
![Money]( "Circle Economics And A Man Made In America")
5/21/2020Inspiration and "circle economics" could help shape your outsourcing decisions. And who knows: It all might end up supporting a more robust national drug-manufacturing infrastructure.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.